Opioid Use Disorder: Treatment with Injectable and Implantable Buprenorphine, Report to Congressional Committees [open pdf - 759KB]
From the Highlights: "In 2018, SAMHSA [Substance Abuse and Mental Health Services Administration] estimated that about one-quarter of the estimated 2 million people with OUD [opioid use disorder] had received some form of substance use treatment in the prior year. One form of treatment--medication-assisted treatment (MAT)-- combines behavioral therapy with the use of certain medications. HHS has identified expanding access to treatment for OUD as an important strategy for reducing opioid morbidity and mortality, which includes increasing the number of injectable and implantable buprenorphine prescriptions. Congress included a provision in the SUPPORT [Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities] Act for GAO [Government Accountability Office] to review access to and the potential for the diversion of controlled substances administered by injection or implantation. This report focuses on injectable and implantable controlled substances that can be used to treat OUD and specifically, describes the process for treating OUD with injectable and implantable buprenorphine and what is known about their use."
Government Accountability Office: https://www.gao.gov/